Kamira Maharaj

Kamira Maharaj

Auto-generated profile, based on publicly available information

Kamira Maharaj

Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KMKamira Maharaj
Kamira Maharaj
JPJohn J. Powers
John J. Powers
AAAlex Achille
Alex Achille
MMMelanie Mediavilla-Varela
Melanie Mediavilla-Varela
WGWael Gamal
Wael Gamal
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of adverse events has led to frequent discontinuations, limiting the clinical development of these inhibitors. By contrast, the dual PI3Kδ/casein kinase-1-ε (CK1ε) inhibitor umbralisib (TGR-1202) also shows high rates of response in clinical trials but has an improved safety profile with fewer severe adverse events. Toxicities typical of this class of PI3K inhibitors are largely thought to be immune mediated, but they are poorly characterized. Here, we report the effects of idelalisib, duvelisib, and umbralisib on regulatory T cells (Tregs) on normal human T cells, T cells from CLL patients, and T cells in an Eμ-TCL1 adoptive transfer mouse CLL model. Ex vivo studies revealed differential effects of these PI3K inhibitors; only umbralisib treatment sustained normal and CLL-associated FoxP3+ human Tregs. Further, although all 3 inhibitors exhibit antitumor efficacy in the Eμ-TCL1 CLL model, idelalisib- or duvelisib-treated mice displayed increased immune-mediated toxicities, impaired function, and reduced numbers of Tregs, whereas Treg number and function were preserved in umbralisib-treated CLL-bearing mice. Finally, our studies demonstrate that inhibition of CK1ε can improve CLL Treg number and function. Interestingly, CK1ε inhibition mitigated impairment of CLL Tregs by PI3K inhibitors in combination treatment. These results suggest that the improved safety profile of umbralisib is due to its role as a dual PI3Kδ/CK1ε inhibitor that preserves Treg number and function.

13 November 2018 in Blood Advances
Verified
Journal Article
Closed access
KMKamira Maharaj
Kamira Maharaj
JPJohn J. Powers
John J. Powers
AAAlex Achille
Alex Achille
SDSusan Deng
Susan Deng
RFRenee Fonseca
Renee Fonseca
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered roles for epigenetic modification in the regulation of mechanisms contributing to malignant progression of CLL B cells. However, the extent to which epigenetic modifiers can be targeted for therapeutic benefit in CLL patients remains poorly explored. We report for the first time that expression of epigenetic modifier histone deacetylase 6 (HDAC6) is upregulated in CLL patient samples, cell lines, and euTCL1 transgenic mouse models compared with HDAC6 in normal controls. Genetic silencing of HDAC6 conferred survival benefit in euTCL1 mice. Administration of isoform-specific HDAC6 inhibitor ACY738 in the euTCL1 aging and adoptive transfer models deterred proliferation of CLL B cells, delayed disease onset via disruption of B-cell receptor signaling, and sensitized CLL B cells to apoptosis. Furthermore, coadministration of ACY738 and ibrutinib displayed synergistic cell kill against CLL cell lines and improved overall survival compared with either single agent in vivo. These results demonstrate for the first time the therapeutic efficacy of selective HDAC6 inhibition in preclinical CLL models and suggest a rationale for the clinical development of HDAC6 inhibitors for CLL treatment, either alone or in combination with Bruton tyrosine kinase inhibition.

16 October 2025 in Blood Advances
Verified
Journal Article
Open access
AUAngimar Uriepero-Palma
Angimar Uriepero-Palma
MMMaria Elena Márquez
Maria Elena Márquez
EPEugenia Payque
Eugenia Payque
MMMelanie Mediavilla-Varela
Melanie Mediavilla-Varela
WGWael Gamal
Wael Gamal
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
Chronic lymphocytic leukemia (CLL) presents challenges in treatment despite advancements in targeted therapies, often facing resistance or relapse. Chronic inflammation plays a significant role in CLL biology, with heightened inflammatory responses and immune dysfunction. Elevated levels of inflammatory cytokines support this notion. Activating signaling pathways such as NF-κB, Phosphoinositide 3-kinase delta (PI3Kδ), and MAPK via B-cell receptors and CD40 confers advantages to leukemic lymphocytes. Our research focuses on the proinflammatory protein S100A9 in CLL progression. We previously described that patients with CLL release exosomes containing S100A9 during disease progression, correlating with NF-κB activation. S100A9, known for its role in autoimmune diseases and cancers, modulates the antitumor immune response by influencing myeloid-derived suppressor cells. Receptors for S100A9 include Toll-like receptor 4, receptor for advanced glycation end products, and extracellular matrix metalloproteinase inducer (EMMPRIN). We identified a novel molecular mechanism involving the S100A9-EMMPRIN interaction in CLL using primary cells and an in vivo CLL mouse model (Eμ-TCL1). Additionally, we developed an Eμ-TCL1/S100A9–/– mouse model and explored pharmacological targeting of S100A9 in a patient-derived xenograft model, highlighting S100A9 as a promising therapeutic target in CLL with potential clinical applications.

1 June 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
KBKimberly Badal
Kimberly Badal
NMNalisha Monroe
Nalisha Monroe
AMAlisha Mohamed
Alisha Mohamed
AMAkash Maniam
Akash Maniam
MBMichelle Badal
Michelle Badal
KMKamira Maharaj
Kamira Maharaj
PURPOSE: Cancer patient navigation (CPN) training programs in the United States do not address the unique challenges of limited-resource settings. This study evaluates knowledge acquisition, utilization, and participant feedback from the Caribbean Cancer Research Institute's (CCRI) CPN training program, which trained participants from the Caribbean, Botswana, and Kenya between 2018 and 2023. METHODS: The CCRI conducted in-person CPN training in 2018 and 2019, paused in 2020 because of the COVID-19 pandemic, and transitioned to a virtual format in 2021. The program, delivered annually, expanded its curriculum and included participants from Kenya and Botswana. Knowledge acquisition was assessed through a 60-question pretest and post-test, and a 23-question program evaluation survey measured participant satisfaction. A follow-up eight-question survey assessed knowledge utilization. Summary statistics were used to describe participant demographics and survey responses, whereas paired t-tests were used to compare pretest and post-test scores. RESULTS: The virtual, self-paced CCRI CPN Training Program covered 11 topics over 12 hours. Between 2018 and 2023, 55 participants enrolled: 80% (n = 44) passed, 18% (n = 10) failed, and 2% (n = 1) did not complete the course. Most participants (95%, n = 52) were from the Caribbean, with 80% (n = 44) from Trinidad and Tobago. Three participants were from Botswana and Kenya. The majority were female (98%, n = 54) and nurses (36%, n = 20), and did not have a personal history of cancer (89%, n = 49). Significant knowledge gains ( P < .001) were observed across all years except 2023. Participants expressed high satisfaction and suggested improvements. Twenty-two percent (n = 6 of 27) secured employment as patient navigators in oncology settings. CONCLUSION: The CCRI CPN training program trained participants across the Caribbean and showed preliminary acceptability in Kenya and Botswana. Strengths include its low-cost, virtual, self-paced format, adaptability to limited-resource settings, and region-specific content. Future efforts will focus on updating training materials and expanding recruitment.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
KMKamira Maharaj
Kamira Maharaj
MMMelanie Mediavilla-Varela
Melanie Mediavilla-Varela
JPJohn J. Powers
John J. Powers
SWSandra Wiley
Sandra Wiley
AUAngimar Uriepero
Angimar Uriepero
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
Phosphatidylinositol-3 kinase (PI3K) delta signaling is essential for CLL B cell survival and proliferation. Several PI3K inhibitors are approved for treatment of CLL, but PI3K inhibitor-induced alterations in T cell function have been correlated with immune-related adverse events (irAEs). Zandelisib is a novel selective PI3Kδ inhibitor in clinical development with an intermittent dosing schedule for treatment of B cell malignancies. Here, we investigated the dynamic immunomodulatory properties of zandelisib alone or in combination with BTK inhibitor ibrutinib in normal human T cells, as well as the impact of continuous dosing of zandelisib on effector and regulatory immune cells, irAEs, and survival in a preclinical CLL murine model. Normal human T cells treated ex vivo with zandelisib, ibrutinib, or both were assessed for phenotype and function. A CLL model was initiated by transferring leukemic EμTCL1 splenocytes into syngeneic wildtype recipients. CLL-bearing mice were treated with vehicle or zandelisib (50 mpk bid or 100 mpk qd) for 3 weeks (n=5 per group). Antitumor efficacy, T cell and myeloid subsets in blood, bone marrow and spleen were analyzed. Survival was also observed in a separate cohort of mice treated with zandelisib (100 mpk qd). T cell proliferation was impaired by zandelisib (250nM) and ibrutinib (100 nM) alone, with the combination further reducing T cell proliferation. Zandelisib decreased expression of suppressive markers PD-1, CTLA-4, GITR and CD39 on iTregs; however, no further decrease was observed when zandelisib was combined with ibrutinib. Zandelisib also reduced normal T cell activation and expression of immune checkpoints PD-1 and CTLA-4 on CD4+ T cells and dose dependently inhibited T cell memory differentiation ex vivo, increasing the naïve/central to effector memory ratio. Combination with ibrutinib did not further affect T cell activation, checkpoint expression or memory differentiation. In the CLL murine model, no meaningful difference was seen between bid or qd administration of zandelisib in the reduction of tumor burden (CD19+ CD5+ CLL cells). Zandelisib treatment reduced activated T cells, antigen-experienced T cells, and Tregs. Increased naïve/central to effector memory ratio was observed in treated mice, and PD-1 was downregulated on memory T cells, indicating less T cell exhaustion. Zandelisib decreased macrophages in the spleen but did not impact myeloid-derived suppressor cells. Zandelisib treatment improved survival of CLL-bearing mice significantly when compared to vehicle group (median survival of zandelisib group 140 days vs. 105 days vehicle). In conclusion, zandelisib treatment reduced Tregs, prevented terminal memory differentiation, and T-cell exhaustion—features that have been shown to permit CLL immune evasion—demonstrated antitumor efficacy, and improved overall survival in a preclinical CLL model. Citation Format: Kamira Maharaj, Melanie Mediavilla-Varela, John J. Powers, Sandra Wiley, Angimar Uriepero, Wael Gamal, Kun Jiang, Eva Sahakian, Javier Pinilla-Ibarz. Efficacy and immune profiling of PI3K delta inhibitor zandelisib (ME-401) in a preclinical chronic lymphocytic leukemia (CLL) model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5496.